This inventor holds 1 USPTO granted patent. Top assignees: Antidote Therapeutics, Inc., Blink Biomedical, Hennepin Healthcare Research Institute. Active years: 2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 3 
1 out of 1 
1 out of 3 Years Active: 2022
Title: Stéphanie Fallot: Innovator in Nicotine Addiction Treatment
Introduction
Stéphanie Fallot is a notable inventor based in Marseilles, France. He has made significant contributions to the field of nicotine addiction treatment through his innovative research and development of novel solutions.
Latest Patents
Stéphanie Fallot holds a patent for nicotine-binding antibodies. This patent describes novel nicotine-binding antibodies and methods for using them to treat nicotine addiction, facilitate smoking cessation, and address nicotine overdose or poisoning. His work in this area is crucial for advancing therapeutic options for individuals struggling with nicotine dependence.
Career Highlights
Throughout his career, Stéphanie has worked with various companies, including Antidote Therapeutics, Inc. and Blink Biomedical. His experience in these organizations has allowed him to develop and refine his innovative ideas, contributing to the advancement of medical treatments for nicotine-related issues.
Collaborations
Stéphanie has collaborated with notable professionals in his field, including Matthew W. Kalnik and Thomas Thisted. These partnerships have enhanced his research and broadened the impact of his inventions.
Conclusion
Stéphanie Fallot's work in developing nicotine-binding antibodies represents a significant advancement in the treatment of nicotine addiction. His innovative approach and collaborations with other experts highlight his commitment to improving public health.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile